9 stories mentioning BCAXUpdated just now
Every FINWIRES story that references BCAX, newest first.
Bicara Therapeutics (BCAX) has an average rating of buy and mean price target of $33.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Ryan Cohlhepp, Director, President and COO, on August 10, 2026, sold 18,750 shares in Bicara Therapeutics (BCAX) for $524,533. Following the Form 4 filing with the SEC, Cohlhepp has control over a total of 181,641 common shares of the company, with 181,641 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/2023658/000147083126000812/xslF345X05/wk-form4_1786565947.xml
Claire Mazumdar, Director, Chief Executive Officer, on August 10, 2026, sold 10,000 shares in Bicara Therapeutics (BCAX) for $279,750. Following the Form 4 filing with the SEC, Mazumdar has control over a total of 362,152 common shares of the company, with 362,152 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/2023658/000147083126000813/xslF345X05/wk-form4_1786565953.xml
Ivan Hyep, Chief Financial Officer, on August 10, 2026, sold 12,500 shares in Bicara Therapeutics (BCAX) for $349,591. Following the Form 4 filing with the SEC, Hyep has control over a total of 129,855 common shares of the company, with 129,855 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/2023658/000147083126000814/xslF345X05/wk-form4_1786565959.xml
Bicara Therapeutics (BCAX) pivotal Fortifi-HN01 study in first-line recurrent/metastatic HPV-negative head and neck cancer remains on track for substantial enrollment by year-end, supporting a mid-2027 interim analysis that could enable accelerated approval, Wedbush Securities said in a Tuesday note.The brokerage noted that Bicara also initiated Fortifi-Flex, evaluating a 12-week weekly loading regimen followed by maintenance dosing every three weeks with pembrolizumab.Wedbush expects the alternative dosing schedule to preserve early TGF-beta suppression and show similar efficacy, with results expected by the time of a potential US accelerated approval.Updated phase 1/1b data showed a three-year overall survival rate of 31%, about double that seen in retrospective pembrolizumab analyses, further supporting the durability of ficerafusp alfa's activity, the brokerage said.Bicara named President and Chief Operating Officer Ryan Cohlhepp as CEO, effective January 2027, succeeding Claire Mazumdar, who will remain Vice Chair and Strategic Advisor. Wedbush does not view the transition as posing meaningful execution risk.Wedbush reiterated its outperform rating and raised its price target to $33 from $30.Shares of Bicara were down nearly 11% in Tuesday afternoon trading.Price: $24.70, Change: $-3.03, Percent Change: -10.93%
Bicara Therapeutics (BCAX) has an average rating of buy and mean price target of $31.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $24.50, Change: $-3.23, Percent Change: -11.65%
Bicara Therapeutics (BCAX) has an average rating of buy and mean price target of $31.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $24.08, Change: $-3.65, Percent Change: -13.16%
Ryan Cohlhepp, Director, President and COO, on July 08, 2026, sold 28,750 shares in Bicara Therapeutics (BCAX) for $833,129. Following the Form 4 filing with the SEC, Cohlhepp has control over a total of 181,641 common shares of the company, with 181,641 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/2023658/000147083126000701/xslF345X05/wk-form4_1783714248.xml
Bicara Therapeutics (BCAX) has an average rating of buy and mean price target of $31.38, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
